Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells

BACKGROUND: Chronic myeloid leukemia (CML) is driven by the fusion kinase Bcr-Abl. Bcr-Abl tyrosine kinase inhibitors (TKIs), such as imatinib mesylate (IM), revolutionized CML therapy. Nevertheless, about 20 % of CMLs display primary or acquired TKI resistance. TKI resistance can be either caused b...

Descripción completa

Detalles Bibliográficos
Autores principales: Halbach, Sebastian, Hu, Zehan, Gretzmeier, Christine, Ellermann, Julia, Wöhrle, Franziska U., Dengjel, Jörn, Brummer, Tilman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765141/
https://www.ncbi.nlm.nih.gov/pubmed/26912052
http://dx.doi.org/10.1186/s12964-016-0129-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4765141/
https://www.ncbi.nlm.nih.gov/pubmed/26912052
http://dx.doi.org/10.1186/s12964-016-0129-y

Ejemplares similares